Combining radiation therapy with dual treatment to improve outcomes in recurrent head and neck cancer.
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
This study is exploring a new way to treat patients with recurring head and neck cancer by combining radiation therapy with two special drugs to boost the immune system and make the treatment work better, which could lead to fewer side effects and improved results for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10915627 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for patients with recurrent head and neck squamous cell carcinoma (HNSCC) by combining radiation therapy with dual inhibition of TGF-beta and PD-L1. The goal is to enhance the immune response against tumors while overcoming resistance to radiation therapy. By using mouse models, the researchers aim to understand how this combination can improve treatment effectiveness and reduce side effects associated with radiation. Patients may benefit from a more effective treatment option that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with locally recurrent head and neck squamous cell carcinoma who have not responded well to standard treatments.
Not a fit: Patients with early-stage head and neck cancer or those who have not yet undergone radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with recurrent head and neck cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using dual inhibition strategies in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Wang, Xiao-Jing — University of Colorado Denver
- Study coordinator: Wang, Xiao-Jing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.